Video

Glaukos COO shares product updates, 2021 pipeline

Author(s):

David Hutton,Alex Delaney-Gesing
Conferences|GLAUCOMA 360

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.


See more Glaucoma 360 coverage

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
Glaukos announces several positive clinical updates for its iDose platform
January 20th 2025

Glaukos announces several positive clinical updates for its iDose platform

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Bausch + Lomb, Glaucoma Research Foundation partner for second annual Faces of Glaucoma campaign
January 8th 2025

Bausch + Lomb, Glaucoma Research Foundation partner for second annual Faces of Glaucoma campaign

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Ophthalmology Times 2024 wrap-up: A year of innovation and insight
December 26th 2024

Ophthalmology Times 2024 wrap-up: A year of innovation and insight

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform
December 20th 2024

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform

© 2025 MJH Life Sciences

All rights reserved.